Knight Therapeutics Inc.

GUD

CA4990531069

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 21:00:00 03/07/2024 BST			5-day change	1st Jan Change
5.75 ^CAD	+0.52%		+4.93%	+10.79%

05-09	Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	MT
05-09	Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Knight Therapeutics Inc. Announces Board Changes

November 08, 2018 at 11:00 am

Knight Therapeutics Inc. accepted the resignation of Dr. Sarit Assouline and appointed Nancy Harrison on the Board of Directors.

Latest news about Knight Therapeutics Inc.

Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	05-09	MT
Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million	05-09	MT
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America	05-09	MT
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024	05-09	CI
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America	05-09	CI
Knight Therapeutics Price Target Raised to $7 at RBC	03-22	MT
Knight Therapeutics Reports Fourth Quarter Results	03-21	MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	03-21	CI
Transcript : Knight Therapeutics Inc., Q4 2023 Earnings Call, Mar 21, 2024	03-21
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Knight Therapeutics Inc. Announces Impairment Charges for the Fourth Quarter of 2023	03-21	CI
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-21	CI
North American Morning Briefing : Investors -2-	03-21	DJ
North American Morning Briefing : Investors Continue to Cheer Reassuring Fed	03-21	DJ
Knight Therapeutics Announces Launch of Minjuvi in Brazil	02-29	MT
Knight Therapeutics Brief: Announcing Launch of Minjuvi in Brazil	02-29	MT
Knight Therapeutics Brief: Announcing Regulatory Submission Of Fostamatinib In Brazil	02-21	MT
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil	02-21	CI
Knight Therapeutics Announces Launch of Bijuva in Canada	02-06	MT
Knight Therapeutics Brief: Announcing Launch of Bijuva in Canada	02-06	MT
Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada	02-06	CI
Amneal Grants Knight Therapeutics Rights to Parkinson's Disease Drug in Canada, Latin America	01-25	MT
Knight Therapeutics Enters Into License Agreement With Amneal Pharmaceuticals For Parkinson's Disease Treatment	01-25	MT

Chart Knight Therapeutics Inc.

Duration

Period

More charts

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Knight Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.75 CAD

Average target price

7.243 CAD

Spread / Average Target

+25.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KNIGHT THERAPEUTICS INC.	+10.79%	423M
MERCK KGAA	+4.96%	70.02B
KYOWA KIRIN CO. LTD.	+20.30%	9.05B
SK BIOPHARMACEUTICALS CO., LTD.	-22.81%	4.43B
YUHAN CORPORATION	+14.83%	4.16B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+19.21%	3.83B
INDIVIOR PLC	-1.86%	2.06B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.78%	2.02B
BETTA PHARMACEUTICALS CO., LTD.	-36.94%	1.9B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-45.25%	1.71B

Specialty & Advanced Pharmaceuticals